Top Cited Articles

Below we have highlighted the top cited articles from each of the last three years to emphasise the important, cutting edge research and reviews published in the journal. We thank these authors for their work and hope they will join us in celebrating another year of growing publications and citations.

ESMO Open is indexed in Science Citation Index-Expanded (Web of Science), PubMed Central, Scopus and the DOAJ.

2019

Implementing TMB measurement in clinical practice: considerations on assay requirements
Reinhard Büttner, John W Longshore, Fernando López-Ríos, et al.
10.1136/esmoopen-2018-000442

Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors
Giovanni Fucà, Giulia Galli, Marta Poggi, et al.
10.1136/esmoopen-2018-000457

Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology
Rosa Giuliani, Josep Tabernero, Fatima Cardoso, et al.
10.1136/esmoopen-2018-000460

Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary roundtable discussion
Anna S. Berghoff, Beatriz Bellosillo, Christophe Caux, et al.
10.1136/esmoopen-2019-000498

How we treat glioblastoma
Michael Weller, Emilie Le Rhun, Matthias Preusser, et al.
10.1136/esmoopen-2019-000520

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events
Esmée P. Hoefsmit, Elisa A. Rozeman, John B. A. G. Haanen, Christian U. Blank
10.1136/esmoopen-2018-000472

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
Lucie Heinzerling, Thomas K Eigentler, Michael Fluck, et al.
10.1136/esmoopen-2019-000491

New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5)
Manuel Piechutta, Anna Sophie Berghoffal
10.1136/esmoopen-2019-000510

Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study
Chiara Cremolini, Matteo Benelli, Elisa Fontana, et al.
10.1136/esmoopen-2019-000489

Phase I clinical trial of decitabine (5-aza-2 ‘-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases
Yanina J L Jansen, Gontran Verset, Kelly Schats, et al.
10.1136/esmoopen-2018-000464

2018

Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management
Marnix H. Geukes Foppen, Elisa A. Rozeman, Sandra van Wilpe, et al.
10.1136/esmoopen-2017-000278

Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion
Matthias Preusser, Frank Winkler, Manuel Valiente, et al.
10.1136/esmoopen-2017-000262

Global cancer control: responding to the growing burden, rising costs and inequalities in access
Gerald W Prager, Sofia Braga, Branislav Bystricky, et al.
10.1136/esmoopen-2017-000285

Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?
Joseph A. Pinto, Carlos S. Vallejos, Luis E. Raez, et al.
10.1136/esmoopen-2018-000344

TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma
Charlotte Leduc, Julien Adam, Emilie Louvet, et al.
10.1136/esmoopen-2017-000257

BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer
Jan Norum, Eli Marie Grindedal, Cecilie Heramb, et al.
10.1136/esmoopen-2018-000328

Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer
Richard M. Goldberg, Clara Montagut, Zev A. Wainberg, et al.
10.1136/esmoopen-2018-000353

How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
Ji Hyun Park, Jin-Hee Ahn, Sung-Bae Kim
10.1136/esmoopen-2018-000357

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case
Erika Martinelli, Teresa Troiani, Vincenzo Sforza, et al.
10.1136/esmoopen-2017-000299

Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability
Junhun Cho, Young Hwan Chang, You Jeong Heo, et al.
10.1136/esmoopen-2018-000326

2017

Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
Clemence Granier, Eleonore De Guillebon, Charlotte Blanc, et al.
10.1136/esmoopen-2017-000213

Cardiotoxicity of immune checkpoint inhibitors
Gilda Varricchi, Maria Rosaria Galdiero, Giancarlo Marone, et al.
10.1136/esmoopen-2017-000247

Multiple primary tumours: challenges and approaches, a review
Alexia Vogt, Sabine Schmid, Karl Heinimann, et al.
10.1136/esmoopen-2017-000172

Targeting immune checkpoints in breast cancer: an update of early results
Cinzia Solinas, Andrea Gombos, Sofiya Latifyan, et al.
10.1136/esmoopen-2017-000255

New treatment options for metastatic renal cell carcinoma
Alejo Rodriguez-Vida, Thomas E. Hutson, Joaquim Bellmunt, et al.
10.1136/esmoopen-2017-000185

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer
Fiona Blackhall, D. Ross Camidge, Alice T. Shaw, et al.
10.1136/esmoopen-2017-000219

Biology of premature ageing in survivors of cancer
Margaret C. Cupit-Link, James L. Kirkland, Kirsten K. Ness, et al.
10.1136/esmoopen-2017-000250

Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer
Makoto Nishio, Toyoaki Hida, Shinji Atagi, et al.
10.1136/esmoopen-2016-000108

Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer
Atsuko Kitano, Makiko Ono, Masayuki Yoshida, et al.
10.1136/esmoopen-2016-000150

Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury
Gary Joseph Doherty, Adam M Duckworth, Susan E Davies, et al.
10.1136/esmoopen-2017-000268